Structural biology experts and service provider responds to market demands
BOSTON, Massachusetts, June 7, 2016 /PRNewswire/ -- HarkerBIO, an industry leader in structural biology drug design support services and early stage drug development programs, announced today the expansion of its executive leadership team with the hiring of contract research organization (CRO) and business development industry veteran, Laura Sailor. Sailor will head the operations for business strategy, marketing and corporate partnerships.
Sailor comments, "I found the opportunity to join the team at HarkerBIO an impossible one to pass up. The company is committed to advancing the science and art of structural biology and recognizes its essential role in bridging the gap between chemistry and biology for drug design. HarkerBIO meets the needs of a void that is expanding in the pharmaceutical industry; reductions in research and development dollars internally are smartly and efficiently spent with experts like HarkerBIO who can manage multiple facets of protein structure determination, saving companies significant resources.”
"Laura has a proven ability to build great teams and successfully bring new technology to the market and I believe she will have a real impact on the solutions we can bring to our customers. She has been a champion of preserving expertise in the industry and creating successful business models in this space, all of which have resulted in advancing drug programs now coming to the clinic," said Artem Evdokimov, CEO and CSO of HarkerBIO.
Prior to joining HarkerBIO, Ms. Sailor held key positions in global business development with three major CROs including WuXi, Aptuit, and CrownBio.
About HarkerBIO
HarkerBIO is the leading contract research organization (CRO) providing high-quality solutions for early stage drug development. Its core expertise lies in the production of pharmaceutically relevant proteins for biophysical screening and protein crystallography. HarkerBIO clients benefit from the company’s proficiencies in protein biochemistry, biophysical characterization, complete gene-to-structure studies, production of difficult to get proteins and protein complexes, rapid solution of new protein structures, iterative fragment and compound screening, and biophysical validation.
HarkerBIO’s investment in experienced people, leading-edge technology, and state-of-the-art laboratory facilities enables them to provide quality capabilities for gene-to-structure research. For more information www.harkerbio.com.
Media Contact:
Laura Sailor, HarkerBIO (603) 995-1076 x2
laura.sailor@harkerbio.com
BOSTON, Massachusetts, June 7, 2016 /PRNewswire/ -- HarkerBIO, an industry leader in structural biology drug design support services and early stage drug development programs, announced today the expansion of its executive leadership team with the hiring of contract research organization (CRO) and business development industry veteran, Laura Sailor. Sailor will head the operations for business strategy, marketing and corporate partnerships.
Sailor comments, "I found the opportunity to join the team at HarkerBIO an impossible one to pass up. The company is committed to advancing the science and art of structural biology and recognizes its essential role in bridging the gap between chemistry and biology for drug design. HarkerBIO meets the needs of a void that is expanding in the pharmaceutical industry; reductions in research and development dollars internally are smartly and efficiently spent with experts like HarkerBIO who can manage multiple facets of protein structure determination, saving companies significant resources.”
"Laura has a proven ability to build great teams and successfully bring new technology to the market and I believe she will have a real impact on the solutions we can bring to our customers. She has been a champion of preserving expertise in the industry and creating successful business models in this space, all of which have resulted in advancing drug programs now coming to the clinic," said Artem Evdokimov, CEO and CSO of HarkerBIO.
Prior to joining HarkerBIO, Ms. Sailor held key positions in global business development with three major CROs including WuXi, Aptuit, and CrownBio.
About HarkerBIO
HarkerBIO is the leading contract research organization (CRO) providing high-quality solutions for early stage drug development. Its core expertise lies in the production of pharmaceutically relevant proteins for biophysical screening and protein crystallography. HarkerBIO clients benefit from the company’s proficiencies in protein biochemistry, biophysical characterization, complete gene-to-structure studies, production of difficult to get proteins and protein complexes, rapid solution of new protein structures, iterative fragment and compound screening, and biophysical validation.
HarkerBIO’s investment in experienced people, leading-edge technology, and state-of-the-art laboratory facilities enables them to provide quality capabilities for gene-to-structure research. For more information www.harkerbio.com.
Media Contact:
Laura Sailor, HarkerBIO (603) 995-1076 x2
laura.sailor@harkerbio.com
